Respiratory syncytial Virus (RSV)

CAS No.	Product Name	Inquiry
1903763-83-6	Sisunatovir hydrochloride Sisunatovir is a highly potent fusion inhibitor with efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses. Sisunatovir exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection.
1963-36-6	para-METHOXY CINNAMIC ALDEHYDE (PMCA) 4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. It effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL.
197366-24-8	RFI-641
1989556-22-0	Nirsevimab Nirsevimab is a monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) infections in infants. Nirsevimab specifically targets the respiratory syncytial virus (RSV) fusion (F) protein, which is essential for viral entry and replication in respiratory cells. By binding to the F protein, nirsevimab prevents RSV from infecting cells and replicating, thereby reducing the likelihood of severe respiratory illness. It is being investigated for the prevention of RSV infection in infants, particularly those at high risk of severe disease. RSV is a common respiratory virus that can cause serious illness, especially in premature infants and those with certain medical conditions.
2070852-76-3	Zelicapavir
2151937-80-1	AVG-233 AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).
2347368-51-6	JNJ-7184
235106-62-4	VP-14637 VP-14637 is a small molecule inhibitor of respiratory syncytial virus (RSV) with EC50 value of 1.4 nM. It suppresses RSV via binding to the viral F protein and inhibiting the RSV fusion (EC50 = 5.4 nM).
2395007-75-5	RSV-IAV-IN-2 RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections.
2395007-77-7	RSV-IAV-IN-1 RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections.
2395007-81-3	RSV-IAV-IN-3 RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage.
2415018-86-7	RSV-IN-5 RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins.
2415152-41-7	RSV-IN-6 RSV-IN-6 (Compound 53) is an anti-RSV agent targeting M2-1 protein with EC50 values of 4.4 μM and 1.3 μM against RSV-A and RSV-B strain, respectively.
2429913-18-6	Clesrovimab
2448519-26-2	RSV-IN-2 RSV-IN-2 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins.
2711039-08-4	ACSS2-IN-1 ACSS2-IN-1 is a potent ACSS2 inhibitor used in the treatment of cancer.
2779498-79-0	Mindeudesivir hydrobromide
312615-62-6	Antiviral agent 10 Antiviral agent 10 is an antiviral agent and it can inhibit respiratory syncytial virus (RSV).
317846-22-3	JNJ-2408068 JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and 2.1 nM, respectively.
381731-49-3	Antiviral agent 30

※ Please kindly note that our services are for research use only.